Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Finished Goods (2017 - 2025)

Historic Finished Goods for Adma Biologics (ADMA) over the last 9 years, with Q3 2025 value amounting to $64.3 million.

  • Adma Biologics' Finished Goods rose 201.99% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 201.99%. This contributed to the annual value of $48.1 million for FY2024, which is 3153.54% down from last year.
  • Adma Biologics' Finished Goods amounted to $64.3 million in Q3 2025, which was up 201.99% from $47.9 million recorded in Q2 2025.
  • Adma Biologics' 5-year Finished Goods high stood at $70.3 million for Q4 2023, and its period low was $17.5 million during Q2 2021.
  • For the 5-year period, Adma Biologics' Finished Goods averaged around $51.5 million, with its median value being $53.7 million (2023).
  • As far as peak fluctuations go, Adma Biologics' Finished Goods soared by 25715.55% in 2022, and later crashed by 3247.38% in 2025.
  • Adma Biologics' Finished Goods (Quarter) stood at $29.0 million in 2021, then skyrocketed by 101.6% to $58.5 million in 2022, then grew by 20.22% to $70.3 million in 2023, then crashed by 31.54% to $48.1 million in 2024, then skyrocketed by 33.72% to $64.3 million in 2025.
  • Its Finished Goods stands at $64.3 million for Q3 2025, versus $47.9 million for Q2 2025 and $46.6 million for Q1 2025.